Publications by authors named "Bernd Adami"
Aim: To investigate the efficacy and safety of cape-citabine plus irinotecan +/- bevacizumab in advanced or metastatic colorectal cancer patients.
Methods: Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer (mCRC) were recruited between 2001-2006 in a prospective open-label phase II trial, in German community-based outpatient clinics. Patients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regimen every 3 wk.
Background: Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer. However, in light of safety and efficacy concerns, the best combination regimen for first-line therapy still needs to be defined. The current study reports on the bimonthly FOLFIRI protocol consisting of irinotecan with continuous FA/5-FU in five German outpatient clinics, with emphasis on the safety and efficiency, quality of life, management of delayed diarrhea, and secondary resection of regressive liver metastases.
View Article and Find Full Text PDFArticle Synopsis
- * A study with 46 patients in Germany reported manageable toxicity, with significant side effects like diarrhea and leukopenia, but treatment was mostly well tolerated, and adjusted for patient health.
- * The treatment resulted in a 35% overall response rate, with notable instances of stable disease and resectable liver metastases, indicating the need for further research into its use in neoadjuvant therapies.